← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Triptorelin

FDA approved · Rx

GnRH agonist peptide

Also known as: Trelstar, Triptodur, Triptoreline, Triptorelina, Arvekap, Triptorelinum, (D-Trp6)-GnRH, tryptorelin

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 298 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH), a decapeptide sold under the brand names Trelstar and Triptodur. It initially stimulates the pituitary, but continued exposure desensitizes GnRH receptors, which lowers the release of LH and FSH and reduces sex hormone production such as testosterone and estrogen.

What the evidence shows

Automatic summaryHuman trials

Triptorelin is FDA approved for palliative treatment of advanced prostate cancer (Trelstar) and for central precocious puberty in children (Triptodur), supported by a large body of human research including nearly 300 registered trials. Uses outside these approved indications are less established and depend on the specific condition studied.

Key facts

Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

298registered studies
Phase 4most advanced phase
47completed (sample)
11recruiting (sample)

the Effects of GnRHa Add up to Routine Luteal Phase Support on Frozen Embryo Implantation in Frozen Embryo Transfer .

Phase 4UnknownNCT02655146

Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

Phase 4UnknownNCT00417183

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

Phase 4CompletedNCT00417066

Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS

UnknownNCT02827656

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,049papers referencing Triptorelin

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

N Engl J Med2014

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

JAMA2011

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

Lancet Oncol2020

A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.

Hum Reprod2005

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.